<?xml version="1.0" encoding="UTF-8"?>
<p>We conducted a randomised trial to determine the vaccine immunogenicity of standard versus enhanced IIV in community‐dwelling older adults, 65–82 years old, which was initiated before the 2017/2018 winter influenza season in Hong Kong (
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">http://ClinicalTrials.gov</ext-link> NCT03330132). Older adults (Supplementary table 
 <xref rid="cti21107-sup-0002" ref-type="supplementary-material">1</xref>) were randomly allocated to receive the 2017/2018 WHO‐recommended IIV formulation of either standard FluQuadri IIV (S‐IIV) or one of three enhanced vaccines adjuvanted (FluAd, A‐eIIV), recombinant HA (FluBlok, R‐eIIV) and high dose (FluZone high dose, H‐eIIV) (Table 
 <xref rid="cti21107-tbl-0001" ref-type="table">1</xref>).
 <xref rid="cti21107-bib-0018" ref-type="ref">18</xref> Plasma was isolated from blood samples at baseline (day 0), and after vaccination at days 7 (acute) and 30 (short‐term memory) (Figure 
 <xref rid="cti21107-fig-0001" ref-type="fig">1</xref>a). Standard HAI serological responses and T‐cell responses are reported elsewhere.
 <xref rid="cti21107-bib-0018" ref-type="ref">18</xref> All participants provided written informed consent. The study protocol was approved by the Institutional Review Board of the University of Hong Kong (UW:16‐2014).
</p>
